Loading...

co.don

DB:CNWK
Snowflake Description

Flawless balance sheet with high growth potential.

The Snowflake is generated from 30 checks in 5 different areas, read more below.
CNWK
DB
€97M
Market Cap
  1. Home
  2. DE
  3. Pharmaceuticals & Biotech
Company description

co.don AG engages in cell cultivation for the regenerative treatment of articular cartilage and spinal disc defects worldwide. The last earnings update was 231 days ago. More info.


Add to Portfolio Compare Print
  • co.don has significant price volatility in the past 3 months.
CNWK Share Price and Events
7 Day Returns
-8.3%
DB:CNWK
-1.4%
DE Biotechs
2.4%
DE Market
1 Year Returns
-28.9%
DB:CNWK
-10.6%
DE Biotechs
-6.2%
DE Market
CNWK Shareholder Return
  7 Day 30 Day 90 Day 1 Year 3 Year 5 Year
co.don (CNWK) -8.3% 17.3% 44.6% -28.9% 82.4% 63.5%
DE Biotechs -1.4% 2.6% -7.7% -10.6% 54.2% 8%
DE Market 2.4% 3% 7.4% -6.2% 9.6% 14.1%
1 Year Return vs Industry and Market
  • CNWK underperformed the Biotechs industry which returned -10.6% over the past year.
  • CNWK underperformed the Market in Germany which returned -6.2% over the past year.
Price Volatility
CNWK
Industry
5yr Volatility vs Market

Value

 Is co.don undervalued based on future cash flows and its price relative to the stock market?

Value is all about what a company is worth versus what price it is available for. If you went into a grocery store and all the bananas were on sale at half price, they could be considered undervalued.
INTRINSIC VALUE BASED ON FUTURE CASH FLOWS
Here we compare the current share price of co.don to its discounted cash flow analysis.value.

The discounted cash flow value is simply looking at what the company is worth today, based on estimates of how much money it is expected to make in the future.
Raw Data

Below are the data sources, inputs and calculation used to determine the intrinsic value for co.don.

DB:CNWK Discounted Cash Flow Data Sources
Data Point Source Value
Valuation Model 2 Stage Free Cash Flow to Equity
Levered Free Cash Flow Average of 2 Analyst Estimates (S&P Global) See below
Discount Rate (Cost of Equity) See below 8%
Perpetual Growth Rate 10-Year DE Government Bond Rate 0.2%

An important part of a discounted cash flow is the discount rate, below we explain how it has been calculated.

Calculation of Discount Rate/ Cost of Equity for DB:CNWK
Data Point Calculation/ Source Result
Risk-Free Rate 10-Year DE Govt Bond Rate 0.2%
Equity Risk Premium S&P Global 6%
Biotechs Unlevered Beta Simply Wall St/ S&P Global 1.45
Re-levered Beta = Unlevered beta (1 + (1- tax rate) (Debt/Equity))
= 1.448 (1 + (1- 30%) (0%))
1.3
Levered Beta Levered Beta limited to 0.8 to 2.0
(practical range for a stable firm)
1.3
Discount Rate/ Cost of Equity = Cost of Equity = Risk Free Rate + (Levered Beta * Equity Risk Premium)
= 0.23% + (1.3 * 5.96%)
7.98%

Discounted Cash Flow Calculation for DB:CNWK using 2 Stage Free Cash Flow to Equity Model

The calculations below outline how an intrinsic value for co.don is arrived at by discounting future cash flows to their present value using the 2 stage method. We try to start with analysts estimates of free cash flow, however if these are not available we use the most recent financial results. In the 1st stage we continue to grow the free cash flow over a 10 year period, with the growth rate trending towards the perpetual growth rate used in the 2nd stage. The 2nd stage assumes the company grows at a stable rate into perpetuity.

DB:CNWK DCF 1st Stage: Next 10 year cash flow forecast
Levered FCF (EUR, Millions) Source Present Value
Discounted (@ 7.98%)
2019 -5.50 Analyst x2 -5.09
2020 -3.75 Analyst x2 -3.22
2021 1.30 Analyst x1 1.03
2022 1.94 Est @ 49.13% 1.43
2023 2.61 Est @ 34.46% 1.78
2024 3.24 Est @ 24.19% 2.04
2025 3.79 Est @ 17% 2.21
2026 4.24 Est @ 11.97% 2.30
2027 4.60 Est @ 8.45% 2.31
2028 4.87 Est @ 5.98% 2.26
Present value of next 10 years cash flows €7.04
DB:CNWK DCF 2nd Stage: Terminal Value
Calculation Result
Terminal Value = FCF2028 × (1 + g) ÷ (Discount Rate – g)
= €4.87 × (1 + 0.23%) ÷ (7.98% – 0.23%)
€63.06
Present Value of Terminal Value = Terminal Value ÷ (1 + r)10
= €63.06 ÷ (1 + 7.98%)10
€29.27
DB:CNWK Total Equity Value
Calculation Result
Total Equity Value = Present value of next 10 years cash flows + Terminal Value
= €7.04 + €29.27
€36.32
Equity Value per Share
(EUR)
= Total value / Shares Outstanding
= €36.32 / 20.02
€1.81
DB:CNWK Discount to Share Price
Calculation Result
Value per share (EUR) From above. €1.81
Current discount Discount to share price of €4.86
= -1 x (€4.86 - €1.81) / €1.81
-168%

Learn more about our DCF calculations in Simply Wall St’s analysis model .

  • The current share price of co.don is above its future cash flow value.
Often investors are willing to pay a premium for a company that has a high dividend or the potential for future growth.
PRICE RELATIVE TO MARKET
We can also value a company based on what the stock market is willing to pay for it. This is similar to the price of fruit (e.g. Mangoes or Avocados) increasing when they are out of season, or how much your home is worth.

The amount the stock market is willing to pay for co.don's earnings, growth and assets is considered below, and whether this is a fair price.
Price based on past earnings
Are co.don's earnings available for a low price, and how does this compare to other companies in the same industry?
Raw Data
DB:CNWK PE (Price to Earnings) Ratio Data Sources
Data Point Source Value
Earnings Per Share * Company Filings (2018-06-30) in EUR €-0.36
DB:CNWK Share Price ** DB (2019-04-18) in EUR €4.86
Europe Biotechs Industry PE Ratio Median Figure of 30 Publicly-Listed Biotechs Companies 22.41x
Germany Market PE Ratio Median Figure of 422 Publicly-Listed Companies 19.67x

* Trailing twelve months (TTM) annual GAAP earnings per share excluding extraordinary items.

** Primary Listing of co.don.

DB:CNWK PE (Price to Earnings) Ratio Calculation
Calculation Outcome
PE Ratio

= DB:CNWK Share Price ÷ EPS (both in EUR)

= 4.86 ÷ -0.36

-13.41x

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • co.don is loss making, we can't compare its value to the Europe Biotechs industry average.
  • co.don is loss making, we can't compare the value of its earnings to the Germany market.
Price based on expected Growth
Does co.don's expected growth come at a high price?
Raw Data
DB:CNWK PEG (Price to Earnings to Growth) Ratio Data Sources
Data Point Source Value
PE Ratio See PE Ratio Section -13.41x
Net Income Annual Growth Rate See Future Growth Section.
Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts
41.6%per year
Europe Biotechs Industry PEG Ratio Median Figure of 22 Publicly-Listed Biotechs Companies 1.3x
Germany Market PEG Ratio Median Figure of 270 Publicly-Listed Companies 1.58x

*Line of best fit is calculated by linear regression .

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to calculate PEG ratio for co.don, we can't assess if its growth is good value.
Price based on value of assets
What value do investors place on co.don's assets?
Raw Data
DB:CNWK PB (Price to Book) Ratio Data Sources
Data Point Source Value
Book Value per Share Company Filings (2018-06-30) in EUR €0.83
DB:CNWK Share Price * DB (2019-04-18) in EUR €4.86
Germany Biotechs Industry PB Ratio Median Figure of 15 Publicly-Listed Biotechs Companies 3.71x
Germany Market PB Ratio Median Figure of 570 Publicly-Listed Companies 1.85x
DB:CNWK PB (Price to Book) Ratio Calculation
Calculation Outcome
PB Ratio

= DB:CNWK Share Price ÷ Book Value per Share (both in EUR)

= 4.86 ÷ 0.83

5.84x

* Primary Listing of co.don.

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • co.don is overvalued based on assets compared to the DE Biotechs industry average.
X
Value checks
We assess co.don's value by looking at:
  1. Is the discounted cash flow value less than 20%, or 40% of the share price? (2 checks) ( Click here or on bar chart for details of DCF calculation. )
  2. Is the PE ratio less than the market average, and/ or less than the Biotechs industry average (and greater than 0)? (2 checks)
  3. Is the PEG ratio within a reasonable range (0 to 1)? (1 check)
  4. Is the PB ratio less than the Biotechs industry average (and greater than 0)? (1 check)
  5. co.don has a total score of 0/6, see the detailed checks below.

    Note: We use GAAP Earnings per Share in all our calculations including PE and PEG Ratio.

    Full details on the Value part of the Simply Wall St company analysis model.

Future Performance

 How is co.don expected to perform in the next 1 to 3 years based on estimates from 2 analysts?

The future performance of a company is measured in the same way as past performance, by looking at estimated growth and how much profit it is expected to make.

Future estimates come from professional analysts. Just like forecasting the weather, they don’t always get it right!
Annual Growth Rate
41.6%
Expected annual growth in earnings.
Earnings growth vs Low Risk Savings
Is co.don expected to grow at an attractive rate?
  • co.don's earnings growth is expected to exceed the low risk savings rate of 0.2%.
Growth vs Market Checks
  • co.don's earnings growth is expected to exceed the Germany market average.
  • co.don's revenue growth is expected to exceed the Germany market average.
Annual Growth Rates Comparison
Raw Data
DB:CNWK Future Growth Rates Data Sources
Data Point Source Value (per year)
DB:CNWK Future Earnings Growth Rate Line of Best Fit* through Consensus Estimate Earnings of 2 Analysts 41.6%
DB:CNWK Future Revenue Growth Rate Line of Best Fit* through Consensus Estimate Revenue of 2 Analysts 35.1%
Germany Biotechs Industry Earnings Growth Rate Market Cap Weighted Average 47.5%
Germany Biotechs Industry Revenue Growth Rate Market Cap Weighted Average 26%
Germany Market Earnings Growth Rate Market Cap Weighted Average 11.5%
Germany Market Revenue Growth Rate Market Cap Weighted Average 4.8%

*Line of best fit is calculated by linear regression .

Industry and Market average data is calculated daily.

Learn more about our growth rate calculations in Simply Wall St’s analysis model.

Analysts growth expectations
Raw Data
DB:CNWK Analysts Growth Expectations Data Sources
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
All numbers in EUR Millions and using Trailing twelve months (TTM) annual period rather than quarterly.
DB:CNWK Future Estimates Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income * Avg. No. Analysts
2023-12-31 35 2
2022-12-31 26 2
2021-12-31 18 2 0 2
2020-12-31 11 -3 -4 2
2019-12-31 8 -5 -6 2
2018-12-31 6 -7 -7 2
DB:CNWK Past Financials Data
Date (Data in EUR Millions) Revenue Cash Flow Net Income *
2018-06-30 6 -8
2018-03-31 6 -8
2017-12-31 6 -6 -7
2017-09-30 6 -6
2017-06-30 6 -5
2017-03-31 6 -4
2016-12-31 6 -4 -4
2016-09-30 6 -3
2016-06-30 6 -3
2016-03-31 5 -3
2015-12-31 5 -3 -3
2015-09-30 5 -2

*GAAP earnings excluding extraordinary items.

Super high growth metrics
High Growth Checks
  • co.don's earnings are expected to grow significantly at over 20% yearly.
  • co.don's revenue is expected to grow significantly at over 20% yearly.
Past and Future Earnings per Share
The accuracy of the analysts who estimate the future performance data can be gauged below. We look back 3 years and see if they were any good at predicting what actually occurred. We also show the highest and lowest estimates looking forward to see if there is a wide range.
Raw Data
DB:CNWK Past and Future Earnings per Share
Data Point Source Value
Past Financials Company Filings (9 months ago) See Below
Future Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below

All data from co.don Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:CNWK Future Estimates Data
Date (Data in EUR Millions) EPS * EPS High Estimate EPS Low Estimate Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31 0.00 0.00 0.00 1.00
2020-12-31 -0.20 -0.17 -0.22 2.00
2019-12-31 -0.32 -0.28 -0.35 2.00
2018-12-31 -0.36 -0.32 -0.39 2.00
DB:CNWK Past Financials Data
Date (Data in EUR Millions) EPS *
2018-06-30
2018-03-31
2017-12-31 -0.36
2017-09-30 -0.30
2017-06-30
2017-03-31
2016-12-31 -0.23
2016-09-30 -0.21
2016-06-30
2016-03-31
2015-12-31 -0.18
2015-09-30 -0.15

*GAAP earnings excluding extraordinary items.

Performance in 3 years
In the same way as past performance we look at the future estimated return (profit) compared to the available funds. We do this looking forward 3 years.
  • Unable to establish if co.don will efficiently use shareholders’ funds in the future (Return on Equity greater than 20%) as it is not expected to be profitable.
X
Future performance checks
We assess co.don's future performance by looking at:
  1. Is the annual earnings growth rate expected to beat the low risk savings rate, plus a premium to keep pace with inflation?
  2. Is the annual earnings growth rate expected to beat the average growth rate in earnings of the Germany market? (1 check)
  3. Is the annual revenue growth rate expected to beat the average growth rate in revenue of the Germany market? (1 check)
  4. Is the annual earnings growth rate expected to be above 20%? (1 check)
  5. Is the annual revenue growth rate expected to be above 20%? (1 check)
  6. Is the Return on Equity in 3 years expected to be over 20%? (1 check)
Some of the above checks will fail if the company is expected to be loss making in the relevant year.
co.don has a total score of 5/6, see the detailed checks below.

Note 1: We use GAAP Net Income Excluding Exceptional Items for our Earnings in all our calculations.

Full details on the Future part of the Simply Wall St company analysis model.

Past Performance

  How has co.don performed over the past 5 years?

  • co.don's last earnings update was 231 days ago.
The past performance of a company can be measured by how much growth it has experienced and how much profit it makes relative to the funds and assets it has available.
Past earnings growth
Below we compare co.don's growth in the last year to its industry (Biotechs).
Past Earnings growth analysis
We also check if the company has grown in the past 5 years, and whether it has maintained that growth in the year.
  • co.don does not make a profit and their year on year earnings growth rate was negative over the past 5 years.
  • Unable to compare co.don's 1-year earnings growth to the 5-year average as it is not currently profitable.
  • Unable to compare co.don's 1-year growth to the Europe Biotechs industry average as it is not currently profitable.
Earnings and Revenue History
co.don's revenue and profit over the past 5 years is shown below, any years where they have experienced a loss will show up in red.
Raw Data

All data from co.don Company Filings, last reported 9 months ago, and in Trailing twelve months (TTM) annual period rather than quarterly.

DB:CNWK Past Revenue, Cash Flow and Net Income Data
Date (Data in EUR Millions) Revenue Net Income * G+A Expenses R&D Expenses
2018-06-30 5.95 -8.45 7.59
2018-03-31 5.97 -7.75 7.27
2017-12-31 5.98 -7.05 6.94
2017-09-30 5.78 -5.92 6.37
2017-06-30 5.59 -4.79 5.80
2017-03-31 5.59 -4.22 5.47
2016-12-31 5.60 -3.65 5.14
2016-09-30 5.63 -3.48 4.88
2016-06-30 5.66 -3.31 4.62
2016-03-31 5.41 -3.09 4.29
2015-12-31 5.16 -2.87 3.96
2015-09-30 5.03 -2.49 3.97
2015-06-30 4.90 -2.11 3.99
2015-03-31 4.71 -2.30 3.92
2014-12-31 4.51 -2.49 3.85
2014-09-30 4.44 -2.69 3.58
2014-06-30 4.36 -2.89 3.31
2014-03-31 4.20 -2.79 3.15
2013-12-31 4.05 -2.68 3.00
2013-09-30 3.66 -2.57 2.62
2013-06-30 3.27 -2.45 2.25
2013-03-31 2.98 -2.41 2.18
2012-12-31 2.69 -2.38 2.12
2012-09-30 2.55 -1.76 2.01
2012-06-30 2.40 -1.13 1.91

*GAAP earnings excluding extraordinary items.

Performance last year
We want to ensure a company is making the most of what it has available. This is done by comparing the return (profit) to a company's available funds, assets and capital.
  • It is difficult to establish if co.don has efficiently used shareholders’ funds last year (Return on Equity greater than 20%) as it is loss-making.
  • It is difficult to establish if co.don has efficiently used its assets last year compared to the Europe Biotechs industry average (Return on Assets) as it is loss-making.
  • It is difficult to establish if co.don improved its use of capital last year versus 3 years ago (Return on Capital Employed) as it is currently loss-making.
X
Past performance checks
We assess co.don's performance over the past 5 years by checking for:
  1. Has earnings increased in past 5 years? (1 check)
  2. Has the earnings growth in the last year exceeded that of the Biotechs industry? (1 check)
  3. Is the recent earnings growth over the last year higher than the average annual growth over the past 5 years? (1 check)
  4. Is the Return on Equity (ROE) higher than 20%? (1 check)
  5. Is the Return on Assets (ROA) above industry average? (1 check)
  6. Has the Return on Capital Employed (ROCE) increased from 3 years ago? (1 check)
The above checks will fail if the company has reported a loss in the most recent earnings report. Some checks require at least 3 or 5 years worth of data.
co.don has a total score of 0/6, see the detailed checks below.

Note: We use GAAP Net Income excluding extraordinary items in all our calculations.

Full details on the Past part of the Simply Wall St company analysis model.

Health

 How is co.don's financial health and their level of debt?

A company's financial position is much like your own financial position, it includes everything you own (assets) and owe (liabilities).

The boxes below represent the relative size of what makes up co.don's finances.

The net worth of a company is the difference between its assets and liabilities.
Net Worth
  • co.don is able to meet its short term (1 year) commitments with its holdings of cash and other short term assets.
  • co.don's cash and other short term assets cover its long term commitments.
Balance sheet
This treemap shows a more detailed breakdown of co.don's finances. If any of them are yellow this indicates they may be out of proportion and red means they relate to one of the checks below.
Assets
Liabilities and shares
The 'shares' portion represents any funds contributed by the owners (shareholders) and any profits.
  • High level of physical assets or inventory.
  • co.don has no debt, it does not need to be covered by short term assets.
Historical Debt
Nearly all companies have debt. Debt in itself isn’t bad, however if the debt is too high, or the company can’t afford to pay the interest on its debts this may have impacts in the future.

The graphic below shows equity (available funds) and debt, we ideally want to see the red area (debt) decreasing.

If there is any debt we look at the companies capability to repay it, and whether the level has increased over the past 5 years.
Raw Data

All data from co.don Company Filings, last reported 9 months ago.

DB:CNWK Past Debt and Equity Data
Date (Data in EUR Millions) Total Equity Total Debt Cash & Short Term Investments
2018-06-30 12.42 0.00 20.29
2018-03-31 12.42 0.00 20.29
2017-12-31 16.18 0.00 12.62
2017-09-30 16.18 0.00 12.62
2017-06-30 5.39 0.00 4.56
2017-03-31 5.39 0.00 4.56
2016-12-31 2.76 0.00 1.98
2016-09-30 2.76 0.00 1.98
2016-06-30 5.18 0.00 3.75
2016-03-31 5.18 0.00 3.75
2015-12-31 6.41 0.00 5.74
2015-09-30 6.41 0.00 5.74
2015-06-30 3.50 0.00 1.74
2015-03-31 3.50 0.00 1.74
2014-12-31 4.29 0.00 4.27
2014-09-30 4.29 0.00 4.27
2014-06-30 5.61 0.00 5.03
2014-03-31 5.61 0.00 5.03
2013-12-31 1.81 0.00 1.20
2013-09-30 1.81 0.00 1.20
2013-06-30 3.53 0.00 1.93
2013-03-31 3.53 0.00 1.93
2012-12-31 4.01 0.00 2.84
2012-09-30 4.01 0.00 2.84
2012-06-30 1.58 0.00 0.53
  • co.don has no debt.
  • co.don has not taken on any debt in the past 5 years.
CASH RUNWAY ANALYSIS

For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.

  • co.don has sufficient cash runway for 2.1 years based on current free cash flow.
  • co.don has sufficient cash runway for 1.8 years if free cash flow continues to grow at historical rates of 46.5% each year.
X
Financial health checks
We assess co.don's financial health by checking for:
  1. Are short term assets greater than short term liabilities? (1 check)
  2. Are short term assets greater than long term liabilities? (1 check)
  3. Has the debt to equity ratio increased in the past 5 years? (1 check)
  4. Is the debt to equity ratio over 40%? (1 check)
  5. Is the debt covered by operating cash flow? (1 check)
  6. Are earnings greater than 5x the interest on debt (if company pays interest at all)? (1 check)
  7. co.don has a total score of 6/6, see the detailed checks below.
For companies that are loss making and have been so on average in the past we replace the last 2 checks with:
  1. Does cash and short term investments cover stable operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)
  2. Does cash and short term investments cover growing operating expenses (recurring G&A and R&D) for more than 3 years? (1 check)


Full details on the Health part of the Simply Wall St company analysis model.

Dividends

 What is co.don's current dividend yield, its reliability and sustainability?

Dividends are regular cash payments to you from the company, similar to a bank paying you interest on a savings account.
Annual Dividend Income
Dividend payments
0%
Current annual income from co.don dividends. Estimated to be 0% next year.
If you bought €2,000 of co.don shares you are expected to receive €0 in your first year as a dividend.
Dividend Amount
Here we look how much dividend is being paid, if any. Is it above what you can get in a savings account? It is up there with the best dividend paying companies?
  • Unable to evaluate co.don's dividend yield against the bottom 25% of dividend payers as the company has not reported any payouts.
  • Unable to evaluate co.don's dividend against the top 25% market benchmark as the company has not reported any payouts.
Annualized Historical and Future Dividends
It is important to see if the dividend for a company is stable, and not wildly increasing/decreasing each year. This graph shows you the historical rate to count toward your assessment of the stock.

We also check to see if the dividend has increased in the past 10 years.
Raw Data
DB:CNWK Annualized Past and Future Dividends
Data Point Source Value
Past Annualized Dividend Yield S&P Global Market Data See Below
Past Dividends per Share Company Filings/ Annualized Dividend Payments See Below
Future Dividends per Share Estimates Average of up to 2 Analyst Estimates (S&P Global) See Below
Europe Biotechs Industry Average Dividend Yield Market Cap Weighted Average of 9 Stocks 0.9%
Germany Market Average Dividend Yield Market Cap Weighted Average of 325 Stocks 3%
Germany Minimum Threshold Dividend Yield 10th Percentile 0.8%
Germany Bottom 25% Dividend Yield 25th Percentile 1.4%
Germany Top 25% Dividend Yield 75th Percentile 3.7%

Industry and Market average data is calculated daily.

Note all dividend per share amounts are annualized and not quarterly or other period.

DB:CNWK Future Dividends Estimate Data
Date (Data in €) Dividend per Share (annual) Avg. No. Analysts
2023-12-31
2022-12-31
2021-12-31
2020-12-31 0.00 1.00
2019-12-31 0.00 1.00
2018-12-31 0.00 1.00

Learn more about our ratios and growth rates in Simply Wall St’s analysis model >

  • Unable to perform a dividend volatility check as co.don has not reported any payouts.
  • Unable to verify if co.don's dividend has been increasing as the company has not reported any payouts.
Current Payout to shareholders
What portion of co.don's earnings are paid to the shareholders as a dividend.
  • Unable to calculate sustainability of dividends as co.don has not reported any payouts.
Future Payout to shareholders
  • No need to calculate the sustainability of co.don's dividends in 3 years as they are not expected to pay a notable one for Germany.
X
Income/ dividend checks
We assess co.don's dividend by checking for:
  1. Firstly is the company paying a notable dividend (greater than 0.8%) - if not then the rest of the checks are ignored.
  2. Is current dividend yield above the bottom 25% of dividend payers? (1 check)
  3. Is current dividend yield above the top 25% of dividend payers? (1 check)
  4. Have they paid a dividend for 10 years, and during this period has the dividend been volatile (drop of more than 25%)? (1 check)
  5. If they have paid a dividend for 10 years has it increased in this time? (1 check)
  6. How sustainable is the dividend, can co.don afford to pay it from its earnings today and in 3 years (Payout ratio less than 90%)? (2 checks)
  7. co.don has a total score of 0/6, see the detailed checks below.


Full details on the Dividends part of the Simply Wall St company analysis model.

Management

 What is the CEO of co.don's salary, the management and board of directors tenure and is there insider trading?

Management is one of the most important areas of a company. We look at unreasonable CEO compensation, how long the team and board of directors have been around for and insider trading.
  • co.don has no CEO, or we have no data on them.
Management Team

Ralf Jakobs

TITLE
CFO & Member of Executive Board
COMPENSATION
€294K
TENURE
2.9 yrs

Matthias Meissner

TITLE
Director of Corporate Communications
Board of Directors Tenure

Average tenure of the co.don board of directors in years:

2.7
Average Tenure
  • The average tenure for the co.don board of directors is less than 3 years, this suggests a new board.
Board of Directors

Hans Bauerfeind

TITLE
Chairman of Supervisory Board
TENURE
1.3 yrs

Bernd Wegener

TITLE
Member of the Supervisory Board
AGE
71

Thommy Stählin

TITLE
Member of the Supervisory Board
TENURE
13.4 yrs

Barbara Sickmüller

TITLE
Member of the Supervisory Board

Thomas Krause

TITLE
Member of the Supervisory Board

Beatrix Bauerfeind-Johnson

TITLE
Member of Supervisory Board
TENURE
2.7 yrs
Who owns this company?
Recent Insider Trading
  • No 3 month insider trading information.
Recent Insider Transactions
Announced Type Name Entity Role Start End Shares Max Price (€) Value (€)
X
Management checks
We assess co.don's management by checking for:
  1. Is the CEO's compensation unreasonable compared to market cap? (1 check)
  2. Has the CEO's compensation increased more than 20% whilst the EPS is down more then 20%? (1 check)
  3. Is the average tenure of the management team less than 2 years? (1 check)
  4. Is the average tenure of the board of directors team less than 3 years? (1 check)
  5. co.don has a total score of 0/6, this is not included on the snowflake, see the detailed checks below.


Note: We use the top 6 management executives and board members in our calculations.

Note 2: Insider trading include any internal stakeholders and these transactions .

Full details on the Management part of the Simply Wall St company analysis model.

News

Simply Wall St News

How Much Of co.don AG (FRA:CNWK) Do Insiders Own?

Institutions will often hold stock in bigger companies, and we expect to see insiders owning a noticeable percentage of the smaller ones. … So it's nice to see some insider ownership, because it may suggest that management is owner-oriented. … Taking a look at our data on the ownership groups (below), it's seems that.

Simply Wall St -

Does co.don AG (FRA:CNWK) Have A High Beta?

Some stocks mimic the volatility of the market quite closely, while others demonstrate muted, exagerrated or uncorrelated price movements. … Some investors use beta as a measure of how much a certain stock is impacted by market risk (volatility). … A stock with a beta greater than one is more sensitive to broader market movements than a stock with a beta of less than one.

Simply Wall St -

What Percentage Of codon AG (FRA:CNWK) Shares Do Insiders Own?

Generally speaking, as a company grows, institutions will increase their ownership. … So it's nice to see some insider ownership, because it may suggest that management is owner-oriented. … Our analysis of the ownership of the company, below, shows that.

Simply Wall St -

Is codon AG (FRA:CNWK) A Financially Sound Company?

codon AG (FRA:CNWK), which has zero-debt on its balance sheet, can maximize capital returns by increasing debt due to its lower cost of capital. … However, the trade-off is CNWK will have to follow strict debt obligations which will reduce its financial flexibility. … Is CNWK right in choosing financial flexibility over lower cost of capital.

Simply Wall St -

How Does codon AG (FRA:CNWK) Affect Your Portfolio Returns?

If you're interested in codon AG (FRA:CNWK), then you might want to consider its beta (a measure of share price volatility) in order to understand how the stock could impact your portfolio. … Beta can be a useful tool to understand how much a stock is influenced by market risk (volatility). … Any stock with a beta of greater than one is considered more volatile than the market, while those with a beta below one are either less volatile or poorly correlated with the market.

Simply Wall St -

How Do Analysts See codon AG (FRA:CNWK) Performing Over The Next Few Years?

The most recent earnings update codon AG's (DB:CNWK) released in December 2017 showed that losses became smaller relative to the prrior year's level as a result of recent tailwinds Below is a brief commentary on my key takeaways on how market analysts predict co.don's earnings growth outlook over the next couple of years and whether the future looks brighter. … The slope of this line is the rate of earnings growth, which in this case is 57.57%. … This means that, we can presume co.don will grow its earnings by 57.57% every year for the next few years.

Simply Wall St -

What Kind Of Risk Should You Expect For codon AG (FRA:CNWK)?

co.don has a beta of 1.18, which means that the percentage change in its stock value will be higher than the entire market in times of booms and busts. … A high level of beta means investors face higher risk associated with potential gains and losses driven by market movements. … According to this value of beta, CNWK may be a stock for investors with a portfolio mainly made up of low-beta stocks.

Simply Wall St -

What Does codon AG's (FRA:CNWK) Ownership Structure Look Like?

Insider Ownership Another important group of shareholders are company insiders. … This size of ownership gives retail investors collective power in deciding on major policy decisions such as executive compensation, appointment of directors and acquisitions of businesses. … As a result, potential investors should further explore the company's business relations with these companies and find out if they can affect shareholder returns in the long-term.Next Steps: With a low level of institutional ownership, investors in CNWK need not worry about non-fundamental factors such as ownership structure causing large impact on stock prices.

Simply Wall St -

When Will codon AG (FRA:CNWK) Become Profitable?

I’ve put together a brief outline of industry analyst expectations for CNWK, its year of breakeven and its implied growth rate. … See our latest analysis for co.don According to the industry analysts covering CNWK, breakeven is near. … So, CNWK is predicted to breakeven approximately 2 years from today.

Simply Wall St -

With A -44.58% Earnings Drop, Did codon AG (FRA:CNWK) Really Underperform?

View our latest analysis for co.don Was CNWK's recent earnings decline indicative of a tough track record? … For the most up-to-date info, I use the ‘latest twelve-month’ data, which annualizes the latest 6-month earnings release, or some times, the latest annual report is already the most recent financial data. … For co.don, its most recent earnings (trailing twelve month) is -€4.79M, which, in comparison to last year’s figure, has become more negative.

Simply Wall St -

Company Info

Description

co.don AG engages in cell cultivation for the regenerative treatment of articular cartilage and spinal disc defects worldwide. The company develops, produces, and markets autologous cell therapies for the minimally invasive repair of cartilage damage to knee joints following traumatic or degenerative defects. Its therapies include matrix-associated autologous cartilage transplantation, a biological therapy for the treatment of damaged articular cartilage with the body's own cells; and autologous chondrocyte transplantation for the regeneration of biomechanical load-bearing and pressure-resistant cartilage tissue. co.don AG was founded in 1993 and is headquartered in Teltow, Germany.

Details
Name: co.don AG
CNWK
Exchange: DB
Founded: 1993
€97,317,407
20,024,158
Website: http://www.codon.de
Address: co.don AG
Warthestrasse 21,
Teltow,
Brandenburg, 14513,
Germany
Listings
Exchange Symbol Ticker Symbol Security Exchange Country Currency Listed on
DB CNWK Common Shares Deutsche Boerse AG DE EUR 14. Feb 2001
XTRA CNWK Common Shares XETRA Trading Platform DE EUR 14. Feb 2001
LSE 0Q37 Common Shares London Stock Exchange GB EUR 14. Feb 2001
BATS-CHIXE CNWKd Common Shares BATS 'Chi-X Europe' GB EUR 14. Feb 2001
Number of employees
Current staff
Staff numbers
97
co.don employees.
Industry
Biotechnology
Pharmaceuticals & Biotech
Company Analysis and Financial Data Status
Area Date (UTC time)
Company Analysis updated: 2019/04/19 20:37
End of day share price update: 2019/04/18 00:00
Last estimates confirmation: 2019/04/12
Last earnings filing: 2018/08/31
Last earnings reported: 2018/06/30
Last annual earnings reported: 2017/12/31


All dates and times in UTC. All financial data provided by Standard & Poor’s Capital IQ.

Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.